Modality
mRNA
MOA
CD3xCD20
Target
PARP
Pathway
Checkpoint
ACCHuntington'sDravet
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
→ Jun 2025
Phase 2Current
NCT03788719
2,630 pts·Huntington's
2018-01→2025-06·Completed
2,630 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0710mo agoPh2 Data· Huntington's
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2025-06-07 · 10mo ago
Huntington's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03788719 | Phase 2 | Huntington's | Completed | 2630 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |